{"id":"vemurafenib-vem","safety":{"commonSideEffects":[{"rate":"~20%","effect":"Arthralgia"},{"rate":"~40%","effect":"Rash"},{"rate":"~30%","effect":"Photosensitivity"},{"rate":"~38%","effect":"Fatigue"},{"rate":"~20%","effect":"Nausea"},{"rate":"~8%","effect":"Alopecia"},{"rate":"~20%","effect":"Cutaneous squamous cell carcinoma"}]},"_chembl":{"chemblId":"CHEMBL1229517","moleculeType":"Small molecule","molecularWeight":"489.93"},"_dailymed":{"setId":"38eea320-7e0c-485a-bc30-98c3c45e2763","title":"ZELBORAF (VEMURAFENIB) TABLET, FILM COATED [GENENTECH, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vemurafenib binds to and inhibits the constitutively active BRAF V600E mutant protein, which drives uncontrolled cell proliferation in melanoma and other malignancies. By blocking this oncogenic kinase, the drug suppresses downstream signaling through the MAPK pathway, leading to cell cycle arrest and apoptosis in BRAF-mutant tumors. This targeted approach is effective primarily in patients whose tumors harbor the BRAF V600E mutation.","oneSentence":"Vemurafenib is a small-molecule inhibitor that selectively blocks the BRAF V600E kinase mutation found in melanoma and other cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:35:36.297Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma with BRAF V600E mutation"},{"name":"Unresectable melanoma with BRAF V600E mutation"}]},"trialDetails":[{"nctId":"NCT05611229","phase":"","title":"Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-16","conditions":"Metastatic Melanoma","enrollment":1975},{"nctId":"NCT01656642","phase":"PHASE1","title":"A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-08-13","conditions":"Malignant Melanoma","enrollment":67},{"nctId":"NCT01897116","phase":"PHASE1","title":"A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2013-06","conditions":"Melanoma","enrollment":8},{"nctId":"NCT01673854","phase":"PHASE2","title":"Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-09-13","conditions":"Melanoma","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vemurafenib (VEM)","genericName":"Vemurafenib (VEM)","companyName":"Abramson Cancer Center at Penn Medicine","companyId":"abramson-cancer-center-at-penn-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vemurafenib (VEM) is a small molecule inhibitor of the serine/threonine-protein kinase B-raf. It is used to treat conditions such as melanoma, malignant melanoma, and metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}